Parse Biosciences, a leading provider of cost-effective and scalable single-cell sequencing solutions, has announced a partnership with Taiwanese company Prisma Biotech to expand its presence in Taiwan and the Asia-Pacific region. “Biotech, pharmaceutical, and academic researchers across Asia are driving demand for Parse’s Evercode single-cell sequencing solutions due to their scalability and simplicity,” said Dr. Alex Rosenberg, CEO and co-founder of Parse Biosciences. “We are excited that through our partnership with Prisma, we can provide researchers the opportunity to leverage the benefits of Parse’s single-cell sequencing technology.”
The agreement with Prisma Biotech will grant more Asian researchers full access to Parse’s single-cell portfolio, including Evercode™ Whole Transcriptome, Evercode TCR, Evercode BCR, Evercode Cell Fixation, Evercode Nuclei Fixation, Gene Select, CRISPR Detect, and Parse Biosciences’ data analytics solution, Trailmaker. This partnership marks a continuation of Parse’s market expansion in Asia, which includes South Korea, Singapore, and India, as well as key international markets like North America, Europe, Australia, Israel, and New Zealand.
“Single-cell sequencing products are in high demand, and Parse’s Evercode technology stands out for its scalability and ease of use,” said Kevin Tseng, CEO of Prisma Biotech. “Our partnership with Parse will make single-cell sequencing accessible to a broad range of researchers in Taiwan and the Asia-Pacific region, and we look forward to supporting the scientific discoveries enabled by these tools.
arse Biosciences is a global life sciences company with a mission to advance human health and scientific research by enabling researchers to effortlessly perform single-cell sequencing at unprecedented scale. This innovative method enables breakthrough discoveries for cancer treatment, kidney and liver disease, tissue repair, stem cell therapy, brain development and the immune system.
Parse was founded on groundbreaking technology developed at the University of Washington. The company has raised over $100 million and is used in nearly 2,000 labs around the world. Its growing product portfolio includes Evercode Whole Transcriptome, Evercode TCR, Evercode BCR, CRISPR Detect, Gene Select, and a data analysis software tool.
Parse Biosciences is headquartered in Seattle, Washington’s vibrant South Lake Union district. The company recently moved into a 34,000 square foot building with a state-of-the-art laboratory.
The source language in which the original text is published is the official and authorized version. Translations are provided for ease of understanding. Only the language version that was originally published is legally binding.
